PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

Johann S.  De Bono

Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical

Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)

Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex

Karim  Fizazi

Honoraria - Astellas Pharma; Janssen; Sanofi

Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Curevac; ESSA; Janssen Oncology; Orion; Roche/Genentech; Sanofi

Travel, Accommodations, Expenses - Amgen; Janssen

Fred  Saad

Honoraria - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Sanofi

Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Sanofi

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst)

Neal D.  Shore

Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Merck; Myovant Sciences; Pfizer; Tolmar

Speakers' Bureau - Bayer; Dendreon; Janssen

Guilhem  Roubaud

No Relationships to Disclose

Mustafa  Ozguroglu

No Relationships to Disclose

Nicolas  Penel

Research Funding - Bayer (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag

Other Relationship - PharmaMar

Nobuaki  Matsubara

Consulting or Advisory Role - Janssen; Sanofi

Research Funding - Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); MSD (Inst)

Niven  Mehra

Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Genzyme; Janssen-Cilag; MSD Oncology; MSD Oncology (Inst); Roche; Roche

Speakers' Bureau - Roche

Research Funding - Astellas Pharma (Inst); Janssen-Cilag (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; MSD Oncology; Roche

Giuseppe  Procopio

Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer

Michael Paul  Kolinsky

Honoraria - Janssen

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; Merck

Kazuo  Nishimura

Honoraria - Astellas Pharma; Novartis

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Janssen

Research Funding - Bayer

Susan  Feyerabend

No Relationships to Disclose

Jae Young  Joung

No Relationships to Disclose

Nicholas J.  Vogelzang

Employment - US Oncology

Stock and Other Ownership Interests  - Caris Life Sciences

Honoraria - Novartis; Pfizer; UpToDate

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Caris Life Sciences; Clovis Oncology; Corvus Pharmaceuticals; Eisai; Genentech/Roche; Janssen Oncology; Merck; Modra Pharmaceuticals; Pfizer; Tolero Pharmaceuticals

Speakers' Bureau - Bayer; Bristol-Myers Squibb; Genentech/Roche; Sanofi

Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst)

Expert Testimony - Novartis

Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; Sanofi/Aventis; US Oncology

Michael Anthony  Carducci

Consulting or Advisory Role - Abbvie; Astellas Pharma; Foundation Medicine; Pfizer; Roche/Genentech

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); pfizer (Inst)

Jinyu  Kang

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Christian Heinrich  Poehlein

Employment - Merck

Leadership - Merck

Stock and Other Ownership Interests  - Merck

Travel, Accommodations, Expenses - Merck

Wenting  Wu

Employment - AstraZeneca

Stock and Other Ownership Interests  - Abbvie (I); Merck

Maha H. A.  Hussain

Honoraria - Astellas Pharma; Astellas Pharma; Genentech; Genzyme; MLI PeerView; Onclive; PER; PER; Phillips Gilmore Oncology; projects in Knowledge; Research to Practice; Sanofi; Sanofi

Consulting or Advisory Role - AstraZeneca; Bayer; Pfizer

Research Funding - AstraZeneca (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst)

Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753

Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Genentech; Genentech/Roche; Pfizer; Sanofi